Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
We determined whether pretreatment anemia predicted for poor outcomes in the setting of early-stage NSCLC treated with stereotactic body radiation therapy (SBRT). Pretreatment hemoglobin levels were evaluated to determine the association with local, regional, and distant control; disease-free survival; and overall survival. Survival rates were estimated with Kaplan-Meier analysis, and multivariate analysis was completed with adjustment for age, T stage, and radiation dose using the Cox proportional hazards model. Receiver operating characteristic curve analysis was used to determine the optimal pretreatment hemoglobin level that would predict for poor outcomes. A total of 147 cases of cases of early-stage NSCLC treated with SBRT were evaluated with a median follow-up of 28.9 months. The 3-year local, regional and distant control rates were 95%, 87%, and 89%, respectively. The 3-year overall survival and disease-free survival rates were 75% and 83%, respectively. On multivariate analysis, a lower pretreatment hemoglobin level predicted for poor regional control, poor disease-free survival, and overall survival (p = 0.02, p = 0.03, p = 0.05, respectively). Pretreatment hemoglobin levels did not predict poor local control. Receiver operating characteristic (ROC) analysis found that pretreatment hemoglobin values less than 12.2 g/dL optimally predicted for poor disease-free survival and regional control. The 3-year disease-free survival for patients with a hemoglobin level of at least 12.2 g/dL was 94% versus 70% in patients with a hemoglobin level less than 12.2 g/dL (p = 0.008). In the setting of SBRT for early-stage NSCLC, we found pretreatment anemia to be predictive of aggressive disease with poor overall survival and nonlocal disease progression.